Reduction of the risk of failure to achieve blood pressure control in patients with arterial hypertension and coronary heart disease: the role of quercetin

Aim. Determine the effect of quercetin on predictors not reaching target blood pressure (BP) levels in patients with arterial hypertension (AH) and coronary heart disease (CHD). Materials methods. 120 stable II stage 2–3 degrees (66 women 54 men) were examined. The divided into 2 groups: Group I – 58 who, addition to basic therapy (ramipril/amlodipine), received (Corvitin®), 62 who only antihypertensive therapy. parameters daily monitoring, lipid spectrum, C-reactive protein, concentration adhesion molecules (s-VCAM, s-ICAM-1), endothelin-1 (ET-1), IL-1, IL-6, TNF-α determined. Statistical processing materials was carried out using following programs: Minitab 21.0, StatPlus Pro 7.6.5, Wizard Pro, Jamovi, MedCalc. Results. We have established that risk level SBP group treatment (group II) significantly increases exceeding LDL >4.0 mmol/l (by 3.6 times), an increase IL-6 >7 ng/ml 10 >9 pg/ml 7 VCAM >1100 2.4 times). In people additionally took I), ET-1 >1.1 pg/ml, failure reach by 2.6 times, 3.5 times toward 8.6 DBP. found > ng/mg arrhythmias 6 II. Conclusions. When is used, it possible achieve values (daily, daytime, nighttime) DBP a higher proportion compared those are prescribed standard Quercetin has endothelial protective effect, as evidenced significant decrease vascular (s-VCAM), type intercellular (s-ICAM-1), ET-1, TNF-α. additional use against background reduces SBP, rhythm disturbances even increased proinflammatory cytokines markers dysfunction.